Valitor Inc. has presented preclinical results on VLTR-559, its long-acting anti-VEGF biologic candidate for durable wet age-related macular degeneration (AMD). VLTR-559, developed using Valitor’s ...

The Senate Appropriations Committee met July 31 to markup legislation that would fund the Department of Health and Human Services – including an additional $400 million for the National Institutes of ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), which looks to be a more reliable biomarker for tracking disease progression ...

Bacteria also defend themselves against pathogen attacks using mechanisms like those of the immune system. But if there is a ...

The BioWorld Drug Developers Index (BDDI) rebounded in the second quarter, ending the first half (H1) of 2025 up 1.23% after ...

The U.S. FDA has cleared Actio Biosciences Inc.’s IND application and granted fast track designation to ABS-1230, an expected ...

Ultromics Ltd. raised $55 million in a series C financing round to expand its commercial footprint across the U.S. and invest in the development of new AI modules for earlier, more accurate detection ...

Astellas Engineered Small Molecules UK Ltd. has outlined compounds reported to be useful for the treatment of mitochondrial disorders.

In a recent publication, researchers from The First Affiliated Hospital of Zhengzhou University (China) and collaborators investigated the association between phosphoglycerate kinase 1 (PGK1) ...

Chengdu Huajian Science Co. Ltd. has patented aromatic hydrazide derivatives reported to be useful for the treatment of cancer.

Beijing Tide Pharmaceutical Co. Ltd. has divulged nanobody-drug conjugates comprising a nanobody targeting B7 homolog 3 (B7-H3, CD276) covalently bound to exatecan through a linker reported to be ...